{
    "root": "ab2b37b1-2e0c-4d70-bc3d-c1469af68fd3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Xcopri",
        "suffix": {
            "text": "Titration Pack"
        }
    },
    "value": "20250430",
    "ingredients": [
        {
            "name": "CENOBAMATE",
            "code": "P85X70RZWS"
        }
    ],
    "indications": "XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.",
    "contraindications": "The recommended initial dosage of XCOPRI is 12.5 mg once daily, titrated to the recommended maintenance dosage of 200 mg once daily.  The recommended titration schedule should not be exceeded.  The maximum dosage is 400 mg once daily. ( 2.1 ) Hepatic impairment: For patients with mild or moderate hepatic impairment, the maximum recommended dosage is 200 mg once daily.  ( 2.2 , 8.7 , 12.3 ) XCOPRI can be taken whole or the tablets can be crushed. The crushed tablet can be mixed with water and either administered by mouth as an oral suspension or administered via a nasogastric tube. ( 2.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "XCOPRI is contraindicated in patients with:\n                  \n                     Hypersensitivity to cenobamate or any of the inactive ingredients in XCOPRI [see Warnings and Precautions (5.1) and Description (11)]\n                     \n                     Familial Short QT syndrome [see Warnings and Precautions (5.2)]"
}